Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation

References

• Warne GT, Jarvis B. Olmesartan medoxomil. Drugs. 2002;62:1345–1353.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165–196.
   PubMed Web of Science ®Google Scholar
• Charman WN, Porter CJH, Mithani S, et al. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci. 1997;86:269–282.
   PubMed Web of Science ®Google Scholar
• Sunesen VH, Vedesdal R, Kristensen HG, et al. Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. Eur J Pharm Sci. 2005;24:297–303.
   PubMed Web of Science ®Google Scholar
• Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278–287.
   PubMed Web of Science ®Google Scholar
• Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231–248.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.
   PubMed Web of Science ®Google Scholar
• Porter CJH, Charman WN. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001;50:61–80.
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47:3–19.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Jianhua Z. Preparation of budesonide nanosuspensions for pulmonary delivery: characterization, in vitro release and in vivo lung distribution studies. Artif Cells Nanomed Biotechnol. 2016;44:285–289.
   PubMed Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56:827–840.
   PubMed Web of Science ®Google Scholar
• Thakkar HP, Patel BV, Thakkar SP. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. J Pharm Bioallied Sci. 2011;3:426–434.
   PubMedGoogle Scholar
• Narendar D, Kishan V. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: pharmacokinetic and pharmacodynamic evaluation. Eur J Pharm Biopharm. 2017;110:47–57.
   PubMed Web of Science ®Google Scholar
• Shamsunder SD, Sandip SC, Krutika KS, et al. Solid lipid nanoparticles and nanosuspension formulation of saquinavir: preparation, characterization, pharmacokinetics and biodistribution studies. J Microencapsul. 2011;28:515–527.
   PubMed Web of Science ®Google Scholar
• Hanafy A, Spahn-Langguth H, Vergnault G, et al. Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev. 2007;59:419–426.
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Release. 2005;107:215–228.
   PubMed Web of Science ®Google Scholar
• Bina G, Amber V. Preparation, characterization, and optimization of altretamine-loaded solid lipid nanoparticles using Box–Behnken design and response surface methodology. Artif Cells Nanomed Biotechnol. 2016;44:571–580.
   PubMed Web of Science ®Google Scholar
• Li W, Yang Y, Tian Y, et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm. 2011;408:157–162.
   PubMed Web of Science ®Google Scholar
• Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95:627–638.
   PubMed Web of Science ®Google Scholar
• Jaydeep P, Garala K, Anjali P, et al. Development of the UV spectrophotometric method of Olmesartan medoxomil in bulk drug and pharmaceutical formulation and stress degradation studies. Pharm Met. 2011;2:36–41.
   PubMedGoogle Scholar
• Pardeike J, Daniela MS, Nina S, et al. Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines. Int J Pharm. 2011;420:93–100.
   PubMed Web of Science ®Google Scholar
• Aji Alex MR, Chacko AJ, Jose S, et al. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42:11–18.
   PubMed Web of Science ®Google Scholar
• Narendar D, Kishan V. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 2016;23:395–404.
   PubMed Web of Science ®Google Scholar
• Vinay Kumar V, Raghavendra C, Rojarani K, et al. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration. Colloids Surf B. 2012;95:1–9.
   PubMed Web of Science ®Google Scholar
• Doktorovova S, Shegokar R, Fernandes L, et al. Trehalose is not a universal solution for solid lipid nanoparticles freeze-drying. Pharm Dev Technol. 2014;19:922–929.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm. 1997;157:171–179.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Caputo O, Carlotti ME, et al. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm. 1997;148:47–54.
   Web of Science ®Google Scholar
• Vinay Kumar V, Chandrasekhar D, Ramakrishna S, et al. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm. 2007;335:167–175.
   PubMed Web of Science ®Google Scholar
• Madhulika P, Deependra S, Manju S. Influence of selected variables on fabrication of Triamcinolone acetonide loaded solid lipid nanoparticles for topical treatment of dermal disorders. Artif Cells Nanomed Biotechnol. 2016;44:392–400.
   PubMed Web of Science ®Google Scholar
• Vijaykumar N, Raviraj P, Venkateshwarlu V, et al. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm Dev Technol. 2009;14:290–298.
   PubMed Web of Science ®Google Scholar
• Shah SK, Asnani AJ, Kawade DP, et al. Simultaneous quantitative analysis of olmesartan medoxomil and amlodipine besylate in plasma by high performance liquid chromatography technique. J Young Pharmacists. 2012;4:88–94.
   PubMedGoogle Scholar
• Müller RH, Becker R, Kruss B, et al. Pharmaceutical nanosuspensions for medicament administration as system of increased saturation solubility and rate of solution. 1998; US Patent, No. 5858410.
   Google Scholar
• Sumeet S, Natarajan J, Kunal J, et al. Olanzapine loaded cationic solid lipid nanoparticles for improved oral bioavailability. Curr Nanosci. 2013;9:26–34.
   Web of Science ®Google Scholar
• Rawat MK, Jain A, Singh S. Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. J Pharm Sci. 2011;100:2366–2378.
   PubMed Web of Science ®Google Scholar
• Grant DJW, Brittian HG. Solubility of pharmaceutical solids. In: Brittian HG, editor. Physical characterization of pharmaceutical solids. New York: Marcel Dekker; 1995. p. 322–380.
   Google Scholar
• Narendar D, Kishan V. Pharmacokinetic and pharmacodynamic studies of nisoldipine loaded solid lipid nanoparticles by central composite design. Drug Dev Ind Pharm. 2015;41:1968–1977.
   PubMed Web of Science ®Google Scholar
• Otsuka M, Kaneniwa N. Effect of seed crystals on solid-state transformation of polymorphs of chloramphenicol palmitate during grinding. J Pharm Sci. 1986;75:506–511.
   PubMed Web of Science ®Google Scholar
• Venkata SKB, Bansilal PG, Sharad CPN, et al. Polymorphic form of olmesartan and process for its preparation. 2006; US Patent No. 20060281800 A1.
   Google Scholar
• Rabea PFJ, Ahmad Z, Iqbal MS, et al. Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies. Drug Dev Ind Pharm. 2014;40:1206–1212.
   PubMed Web of Science ®Google Scholar
• Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008;129:1–10.
   PubMed Web of Science ®Google Scholar